The highly insoluble human epidermal keratin has been the subject of intense investigation in recent years. Its component polypeptides are derived from individual genes and at least two gene families exist giving rise to polypeptides of relative low molecular weight (4657 kDa), with pl 5.G5.5 ('type I'), and a higher molecular weight group of polypeptides (62-70 kDa) with PI 6.G8.5 ('type 11'). The precise involvement of keratins in epidermal disorders such as psoriasis is unclear but there are several reports that in the psoriatic lesion there is reduced synthesis of a high molecular weight component of 'prekeratin' (Hunter & Skerrow, 1982) . ['Prekeratin' was defined by Matoltsy (1964) as the keratin protein from the living epidermal cell layers.] More recently, McGuire et al. (1984) reported identifying at least two polypeptides in epidermis from the psoriatic lesion which were not synthesized in normal epidermis.
We have studied keratin biosynthesis in normal and psoriatic epidermis. Electrokeratotome shavings (0.1 mm) were taken from involved psoriatic lesions of patients who had given informed consent, after first removing superficial scale with a blunt scalpel. Normal skin samples were obtained from a local hair-transplant clinic from patients with no history of skin disorder, and the epidermis removed with an electrokeratotome. In radiolabel incorporation experiments, epidermal shavings were cut into 3 mm squares and incubated in the presence of [35S]methionine (final radioactive concentration 15 pCi/ml) or [3ZP]orthophosphate (final radioactive concentration 0.1 mCi/ml) in Eagle's minimal essential medium at 35°C for 5 h. Incubation was terminated by immersing the epidermis in ice-cold Eagle's minimal essential medium containing no radiolabel. Prekeratin was extracted from living tissue by homogenization and sonication in 0.1 M-citric acid/trisodium citrate buffer, pH 2.65. After centrifugation at 50 0006, prekeratin was partially purified from the supernatant by serial isoelectric precipitation (Matoltsy, 1964) . All prekeratin samples were analysed by SDS/polyacrylamide-gel electrophoresis on 7.5-17.5% gradient slab gels as described by Bowden & Cunliffe (1 98 1). Coomassie Blue-stained SDS/polacrylamide gels were quantified by scanning densitometry. The relative areas under each peak gave a quantitative assessment of the amount of each polypeptide present. Gels containing [32P]~rthophosphate-labelled protein were radioautographed whilst those containing [35S]methioninelabelled protein were fluorographed.
The electrophoretic profiles obtained for psoriatic and normal prekeratin are shown in Fig. 1 . The polypeptides were identified (1-10) following the nomenclature of McGuire et al. (1984) . Comparison of prekeratin from psoriatic lesions and from normal skin ( Fig. 1 ) revealed the presence of extra polypeptides at 54 kDa and at 50 kDa (polypeptide nos. 6 and 8 respectively). In addition, a striking feature of most psoriatic samples was the appearance of a polypeptide at about 44kDa (no. 10) well resolved from the 46kDa polypeptide (no. 9) observed in normal prekeratin. The relative intensities in this doublet (nos. 9 and 10) seemed to be a more reliable indicator of psoriatic prekeratin than was depletion of a high molecular weight Vol. 14 polypeptide(s) previously reported by ourselves and other authors. In our experience the amount of this high molecular weight polypeptide in psoriasis is highly variable from patient to patient, ranging from 'normal' amounts to being virtually absent.
Incubation of psoriatic epidermis with [35S]methionine labelled all of the polypeptides of psoriatic prekeratin. A similar result was obtained with normal scalp epidermis (Bladon et al., 1982) . This implies that all psoriatic prekeratin polypeptides are newly synthesized (i.e. within 5 h) and are not breakdown products. Incubation of psoriatic epidermis with [32P]orthophosphate revealed a preferential incorporation of phosphate into polypeptides of molecular mass 70 kDa, 57 kDa, 52 kDa, or nos 1, 5 and 7 as for 'normal' prekeratin. However, in psoriatic samples where the relative amount of the 70 kDa polypeptide was depleted so too was the intensity of phosphate labelling, i.e. the amount of phosphorylation is proportional to the relative intensity of the band. (1984) . In our gel system (see Bowden & Cunliffe, 1981) the numbers correspond to the molecular masses of the polypeptides as follows: 1, 70 kDa; 2, 66 kDa; 3, 62 kDa; 4, 59 kDa; 5, 57 kDa; 6, 54 kDa; 7, 52 kDa; 8, 50 kDa; 9, 46 kDa; 10, 44 kDa. The anode was at the bottom of the gel. The development stage-and tissue-specific expression of multiple mRNAs encoding a same protein is now a welldocumented phenomenon (Schibler et al., 1983; MacGrogan et al., 1985) . Recently, it has been shown in rat (Mukai et al., 1984; Tsutsumi et al., 1984) that aldolase A is translated from two mRNAs, of 1650 and 1550 bases; the latter was detected in adult muscle, whereas the former was present in brain and re-expressed in hepatomas. Fig. 1 shows a 'Northern' blot analysis of the two aldolase A mRNAs in different rat and human tissues.
BIOCHEMICAL SOCIETY TRANSACTIONS
In rat, the heavier species is the only one detected in non-muscular organs, while the lighter species is the single detectable form in adult gastrocnemius. In foetus, by contrast, only the heavier form was seen before the 19th day of foetal life; then the 1550 base-long mRNA progressively takes over the 1650 one. The lighter aldolase A mRNA species appears to be specific to fast twitch muscle since, by contrast, adult soleus and heart muscle exhibit only the heavier mRNA species, like the non-muscular tissues.
In man, the lighter mRNA form is already present in a 3-month-old foetus muscle, in an equal amount to the heavier species. Also in contrast to the rat, this 1650 base mRNA is still detectable as a minor species in the adult muscle. The peculiar occurrence of slow twitch fibres in human skeletal muscle compared with rat muscle might explain this result. The whole content of aldolase A mRNA is roughly the same in human adult and foetal skeletal muscle, and this is in contrast with the aldolase A protein level, which increases during muscle development. Fig. 2 shows primer extension experiments performed with rat brain, heart and gastrocnemius muscle mRNAs as templates. Adult gastrocnemius allowed a 370 base extension of our primer, while heart and brain mRNA used as templates gave longer extensions, of 420,490 and 560 bases. Therefore, the aldolase A mRNAs present in these tissues differ by their 5' ends. An heterogeneity of the heavier species can be observed in brain and heart.
Discussion
The products of extension using the same primer upon the two types of aldolase A mRNA were different in size; this size difference is of the same range as the size difference between the two mRNAs. Therefore, the 5' end differences can in themselves account for the total difference between those two messengers.
It has been previously demonstrated that a single aldolase A isoenzyme exists in different tissues (Gracy et al., 1970; Ikehara et a]., 1970) and that both heavier and lighter mRNA species have a very homologous, probably identical, 3' non-coding extension (Mukai e t al., 1984). Fig. 1 . Northern blot experimenl Total mRNA was deposited on to each slot. Man: (1) adult liver, 1Opg of mRNA; (2) 3-month-old foetus liver, 10 pg; (3) adult lung, 5 pg; (4) adult muscle, 2 pg; (5) 3-monthold foetus muscle, 4pg; (6) testis, 5 pg; (7) pineal gland, 6pg; (8) adult muscle, 2pg. Rat: (1) 17-day-old foetus muscle, 30 pg; (2) and (10) adult brain, 20pg; (3) 19-day-old foetus muscle, 30pg; (4) and (8) adult gastrocnemius muscle, 3pg; (5) newborn rat muscle, 25 pg; (6) adult soleus muscle, 15 pg; (7) 3-day-old muscle, 18 pg; (9) adult heart, 20 pg; (1 1) 6-day-old muscle, 15 pg.
